Jenna Daniel, PA
Physician Assistant · Versailles, KYNPI 1821390410
Payments from drug & device makers
Across 286 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$982
- GSK$688
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$257
- Axsome Therapeutics, Inc.$200
- AstraZeneca$167
- Lilly USA, LLC$165
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,64999%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 121 | $982 |
| GSK | 56 | $688 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $257 |
| Axsome Therapeutics, Inc. | 8 | $200 |
| AstraZeneca | 10 | $167 |
| Lilly USA, LLC | 9 | $165 |
| Bayer | 7 | $127 |
| Pfizer | 7 | $110 |
| Dexcom, Inc. | 6 | $103 |
| Xeris Pharmaceuticals, Inc. | 4 | $87 |
| Novartis | 5 | $83 |
| Boehringer Ingelheim | 4 | $66 |
| Exact Sciences | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Abbott | 3 | $45 |
| Corcept Therapeutics | 3 | $45 |
| Corium, LLC | 2 | $45 |
| Edwards Lifesciences | 1 | $41 |
| Merck | 3 | $41 |
| Novo Nordisk | 2 | $36 |
| Antares Pharma, Inc. | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Biomerieux Inc | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Radius Health, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$3,698 in reported general payments places this provider in the 85th percentile of 1,448 physician assistant providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 123 | $118,864 |
| TrulicityDulaglutide | 39 | $64,635 |
| OzempicSemaglutide | 24 | $43,021 |
| EliquisApixaban | 62 | $40,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $38,922 |
| RybelsusSemaglutide | 14 | $26,542 |
| RexultiBrexpiprazole | 17 | $25,816 |
| MounjaroTirzepatide | 22 | $22,580 |
| VraylarCariprazine Hcl | 14 | $19,916 |
| EntrestoSacubitril/Valsartan | 15 | $17,832 |
| XareltoRivaroxaban | 26 | $16,388 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $15,916 |
| JanuviaSitagliptin Phosphate | 19 | $14,094 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $13,057 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $12,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $66 | $147,557160 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $165 | $87,21561 claims |
| Novo NordiskOzempic, Rybelsus | $36 | $69,56238 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $688 | $61,89093 claims |
| PfizerEliquis | $110 | $40,89062 claims |
| AbbVieVraylar, Savella | $982 | $31,27232 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $25,81617 claims |
| NovartisEntresto | $83 | $17,83215 claims |
| Johnson & JohnsonXarelto | $16 | $16,38826 claims |
| MerckJanuvia | $41 | $14,09419 claims |
| AstraZenecaBreztri Aerosphere | $167 | $11,86317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,448 physician assistant providers in Kentucky.
Other physician assistant in Versailles
- Lauri GarnerVersailles$33K
- Brandice HarrisonLexington$745K
- Lauren MeadeLexington$656K
- Melissa DavisLouisville$362K
- Kara MuddLouisville$98K
- Seth KingBowling Green$91K
- Marty MullinsHazard$63K
- Robert TatumLouisville$29K
- Michelle JonesLexington$29K
- Grace IsaacsLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.